The Time is Now for Disruptive Innovation in Pre-Exposure Prophylaxis Adherence Monitoring
DOI:
https://doi.org/10.17140/HARTOJ-7-133Keywords:
Pre-exposure prophylaxis, HIV, Adherence, Prevention, Self-reportAbstract
Monitoring adherence to pre-exposure prophylaxis is a critical component of reaching ending the human immunodeficiency virus infection (HIV) epidemic goals in the US. Currently, providers still depend on “self-report” pre-exposure prophylaxis (PrEP) adherence, whereby providers ask their patients about their recent pill taking habits. There appears to be growing consensus across the HIV prevention community that “self-report” is an inadequate method of identifying that is in-need of additional adherence support services. In a recent survey, 97% of providers report utilizing self-reported adherence because it is convenient, but only 10% of these providers believe it is accurate. While “self-report” is convenient, evidence and testimonials from diverse stakeholders across the HIV prevention landscape indicate that there is a desire for more accurate, effective adherence monitoring methods. In this mini-review, we will briefly synthesize the emerging evidence and propose a solution to ensure all patients receive the support needed to protect them from HIV acquisition.
References
McCormack S, Dunn DT, Desai M, Dolling DI, Gafos M, Gil-son R, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): Effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lacentt. 2016; 387(10013): 53-60. doi: 10.1016/S0140-6736(15)00056-2
Anderson PL, Glidden D v., Liu A, Buchbinder S, Lama JR, Guanira JV, et al. Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci Transl Med. 2012; 4(151): 151ra125. doi: 10.1126/scitrans-lmed.3004006
Liu AY, Cohen SE, Vittinghoff E, Anderson PL, Doblecki-Lew-is S, Bacon O, et al. Preexposure prophylaxis for HIV infection integrated with municipal and community-based sexual health ser-vices. JAMA Intern Med. 2016; 176(1): 75-84. doi: 10.1001/jamain-ternmed.2015.4683
Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Var-gas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010; 363(27): 2587- 2599. doi: 10.1056/NEJMoa1011205
Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in botswana. N Engl J Med. 2012; 367(5): 423-434. doi: 10.1056/NEJMoa1110711
Grant RM, Anderson PL, McMahan V, Liu A, Amico KR, Meh-rotra M, et al. Uptake of pre-exposure prophylaxis, sexual prac-tices, and HIV incidence in men and transgender women who have sex with men: A cohort study. Lancet Infect Dis. 2014; 14(9): 820- 829. doi: 10.1016/S1473-3099(14)70847-3
Hojilla JC, Vlahov D, Glidden D v, Amico KR, Mehrotra M, Hance R, et al. Skating on thin ice: stimulant use and sub-optimal adherence to HIV pre-exposure prophylaxis. Journal of the Interna-tional AIDS Society. 2018; 21(3): e25103. doi: 10.1002/jia2.25103
Hosek SG, Siberry G, Bell M, Michelle L, Bill K, Keith G, et al. The acceptability and feasibility of an HIV preexposure pro-phylaxis (PrEP) trial with young men who have sex with men. J Acquir Immune Defic Syndr. 2013; 62(4): 447-456. doi: 10.1097/ QAI.0b013e3182801081
Sidebottom D, Ekström AM, Strömdahl S. A systematic review of adherence to oral pre-exposure prophylaxis for HIV - How can we improve uptake and adherence? BMC Infect Dis. 2018; 18(1): 581. doi: 10.1186/s12879-018-3463-4
Serota D, Rosenberg E, Lockard A, del Rio C, Luisi N, Cutro SR, et al. PrEP persistence and discontinuations. Paper presented in as cohort of young black msm in Atlanta, GA. Paper presented at: Retroviruses and Opportunistic Infections; 2019; Seattle, Wash-ington
Colson PW, Franks J, Wu Y, Winterhalter FS, Knox J, Ortega H, et al. Adherence to pre-exposure prophylaxis in black men who have sex with men and transgender women in a community Set-ting in Harlem, NY. AIDS Behav. 2020. doi: 10.1007/s10461-020- 02901-6
US Department of Health & Human Services. Ready, set, PrEP expands access to medication to prevent HIV. prevention. nih Web site. https://prevention.nih.gov/news-events/news-re-leases/2019/12/ready-set-prep-expands-access-medication-pre-vent-hiv. Accessed December 3, 2019.
Eaton LA, Matthews DD, Bukowski LA, Friedman MR, Chan-dler CJ, Whitfield DL, et al. Elevated HIV prevalence and cor-relates of PrEP use among a community sample of black men 8 Daughtridge G et al who have sex with men. J Acquir Immune Defic Syndr. 2018; 79(3): 339-346. doi: 10.1097/QAI.0000000000001822
Spinelli MA, Haberer JE, Chai PR, Castillo-Mancilla J, Ander-son PL, Gandhi M. Approaches to objectively measure antiretrovi-ral medication adherence and drive adherence interventions. Curr HIV/AIDS Rep. 2020; 17(4): 301-314. doi: 10.1007/s11904-020- 00502-5
Castillo-Mancilla J. Getting it right: practical approaches to ad-herence with modern ARVs. Paper presented at: Retroviruses and Opportunistic Infections; 2020; Boston, Massachusetts, USA.
Castillo-Mancilla JR, Zheng J-H, Rower JE, Meditz A, Gard-ner EM, Predhomme J, et al. Tenofovir, emtricitabine, and teno-fovir diphosphate in dried blood spots for determining recent and cumulative drug exposure. AIDS Res Hum Retroviruses. 2013; 29(2): 384-390. doi: 10.1089/aid.2012.0089
Castillo-Mancilla JR, Morrow M, Coyle RP, Coleman SS, Gard-ner EM, Zheng J-H, et al. Tenofovir diphosphate in dried blood spots is strongly associated with viral suppression in individuals with human immunodeficiency virus infections. Clinical Infectious Diseases. 2019; 68(8): 1335-1342. doi: 10.1093/cid/ciy708
Frasca K, Morrow M, Coyle RP, Coleman SS, Ellison L, Bush-man LR, et al. Emtricitabine triphosphate in dried blood spots is a predictor of viral suppression in HIV infection and reflects short-term adherence to antiretroviral therapy. Journal of Antimicrobial Chemotherapy. 2019; 74(5): 1395-1401. doi: 10.1093/jac/dky559
Gandhi M, Bacchetti P, Ofokotun I, Jin C, Ribaudo HJ, Haas DW, et al. Antiretroviral concentrations in hair strongly predict vi-rologic response in a large human immunodeficiency virus treat-ment-naive clinical trial. Clin Infect Dis. 2019; 68(6): 1044-1047. doi: 10.1093/cid/ciy764
Landovitz RJ, Beymer M, Kofron R, Amico KR, Psaros C, Bushman L, et al. Plasma tenofovir levels to support adherence to TDF/FTC preexposure prophylaxis for HIV prevention in MSM in Los Angeles, California. J Acquir Immune Defic Syndr. 2017; 76(5): 501-511. doi: 10.1097/QAI.0000000000001538
Hebel S, Kahn-Woods E, Larabee L, Osorio B, Mayer KH, Sullivan PS, et al. Uuse of a tenofovir urine test to improve PrEP adherence and predict non-retention. Paper presented at: Retrovi-ruses and Opportunistic Infections; 2020; Boston, Massachusetts, USA.
Gorbach PM, Mensch BS, Husnik M, Coly A, Mâsse B, Maka-nani B, et al. Effect of computer-assisted interviewing on self-re-ported sexual behavior data in a microbicide clinical trial. AIDS Behav. 2013; 17(2): 790-800. doi: 10.1007/s10461-012-0302-2
Baker Z, Javanbakht M, Mierzwa S, Pavel C, Lally M, Zimet Mini Review | Volume 7 | Number 1| G, et al. Predictors of over-reporting HIV pre-exposure prophy-laxis (PrEP) adherence among young men who have sex with men (YMSM) in self-reported versus biomarker data. AIDS Behav. 2018; 22(4): 1174-1183. doi: 10.1007/s10461-017-1958-4
van der Straten A, Brown ER, Marrazzo JM, Chirenje MZ, Liu K, Gomez K, et al. Divergent adherence estimates with phar-macokinetic and behavioural measures in the MTN-003 (VOICE) study. Journal of the International AIDS Society. 2016; 19(1): 20642. doi: 10.7448/IAS.19.1.20642
Musinguzi N, Muganzi CD, Boum Y, Ronald A, Marzinke MA, Hendrix CW, et al. Comparison of subjective and objective adher-ence measures for preexposure prophylaxis against HIV infection among serodiscordant cos in East Africa. AIDS. 2016; 30(7): 1121- 1129. doi: 10.1097/QAD.0000000000001024
Amico KR, Marcus JL, McMahan V, Liu A, Koester K, Goico-chea P, et al. Study product adherence measurement in the iPrEx placebo-controlled trial. J Acquir Immune Defic Syndr. 2014; 66(5): 530-537. doi: 10.1097/QAI.0000000000000216
Birnkrant D. Center for drug evaluation and research applic-aion number. accessdata.fda Web site. https://www.accessdata.fda. gov/drugsatfda_docs/nda/2019/761062Orig1s000Approv.pdf. Accessed June 22, 2020.
Corneli AL, Deese J, Wang M, Taylor D, Ahmed K, Agot K, et al. FEM-PrEP: Adherence patterns and factors associated with ad-herence to a daily oral study product for pre-exposure prophylaxis. J Acquir Immune Defic Syndr. 2014; 66(3): 324-331. doi: 10.1097/ Submit your article to this journal | https://openventio.org/submit-manuscript/ Mini Review | Volume 7 | Number 1| Daughtridge G et al QAI.0000000000000158
Hunt T, Lalley-Chareczko L, Daughtridge G, Swyryn M, Koe-nig H. Challenges to PrEP use and perceptions of urine tenofovir adherence monitoring reported by individuals on PrEP. AIDS Care. 2019; 31(10): 1203-1206. doi: 10.1080/09540121.2019.1587369
Koester KA, Liu A, Eden C, Amico KR, McMahan V, Goicochea P, et al. Acceptability of drug detection monitoring among partici-pants in an open-label pre-exposure prophylaxis study. AIDS Care. 2015; 27(10): 1199-1204. doi: 10.1080/09540121.2015.1039958
Lin D, Zhang CY, He ZK, Zhao XD. How does hard-to-reach status affect antiretroviral therapy adherence in the HIV-infected population? Results from a meta-analysis of observational studies. BMC Public Health. 2019; 19(1). doi: 10.1186/s12889-019-7135-0
Kanters S, Park JJH, Chan K, Socias ME, Ford N, Forrest JI, et al. Interventions to improve adherence to antiretroviral therapy: A systematic review and network meta-analysis. The Lancet HIV. 2017; 4(1): e31-e40. doi: 10.1016/S2352-3018(16)30206-5
Iacob SA, Iacob DG, Jugulete G. Improving the adherence to antiretroviral therapy, a difficult but essential task for a successful HIV treatment-clinical points of view and practical considerations. Front Pharmacol. 2017; 8: 831. doi: 10.3389/fphar.2017.00831
Hunt T, Lalley-Chareczko L, Daughtridge G, Swyryn M, Koe-nig H. Challenges to PrEP use and perceptions of urine tenofovir adherence monitoring reported by individuals on PrEP. AIDS Care. 2019; 31(10): 1203-1206. doi: 10.1080/09540121.2019.1587369
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in HIV/AIDS Research and Treatment (HRT) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.
